Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Companyâs proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Companyâs first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Employees

100

Sector

Pharmaceuticals

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
05/12/25	2.230 $	+0.45%	3,533,532
04/12/25	2.220 $	-0.45%	1,850,093
03/12/25	2.230 $	+3.24%	3,935,274
02/12/25	2.160 $	-13.60%	7,311,057
01/12/25	2.500 $	+2.88%	6,623,299

Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.230USD

Average target price

10.00USD

Spread / Average Target

+348.43%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 05/12/2025 GMT			5-day change	1st Jan Change
2.230 ^USD	+0.45%		-4.29%	+403.27%

11-24	Invivyd Selects Antibody Candidate for Respiratory Syncytial Virus Prevention	MT
11-24	Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329	CI

Capitalization	520M 447M 419M 390M 721M 46.79B 784M 4.9B 1.89B 22.1B 1.95B 1.91B 80.8B	P/E ratio 2025 *	-5.53x	P/E ratio 2026 *	-11.2x
Enterprise value	520M 447M 419M 390M 721M 46.79B 784M 4.9B 1.89B 22.1B 1.95B 1.91B 80.8B	EV / Sales 2025 *	10.2x	EV / Sales 2026 *	3.78x
Free-Float	81.86%	Yield 2025 *	-	Yield 2026 *	-

11-24	Invivyd Selects Antibody Candidate for Respiratory Syncytial Virus Prevention	MT
11-24	Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329	CI
11-18	Invivyd Prices $125 Million Securities Offering; Shares Down Pre-Bell	MT
11-18	Invivyd prices 44 million shares at $2.50 each	RE
11-17	Invivyd Launches Public Stock Offering	MT
11-14	Top Premarket Gainers	MT
11-06	Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-24	Invivyd, Inc., Q3 2025 Earnings Call, Nov 06, 2025
11-06	Invivyd Q3 net loss beats estimates on higher PEMGARDA sales among healthcare providers	RE
10-31	Invivyd, Inc. - Special Call
10-20	Certain Warrants of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025.	CI
10-20	Certain Restricted stock units of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025.	CI
10-20	Certain Options of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025.	CI

10-20	Certain Options of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025.	CI
10-06	Cantor Fitzgerald Initiates Invivyd at Overweight With $10 Price Target	MT
10-06	Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug	DJ
05/04/24	Guggenheim Upgrades Invivyd to Buy From Hold, Price Target is $9	MT
26/03/24	Invivyd Receives Upgrade to Overweight From Equalweight From Morgan Stanley, Price Target Raised to $10 From $4 Amid Pemgarda FDA Authorization	MT

Invivyd, Inc. Share Price

Equities

IVVD

US00534A1025

Pharmaceuticals

Valuation: Invivyd, Inc.

Chart: Invivyd, Inc.

Latest news: Invivyd, Inc.

Last Transcript: Invivyd, Inc.

Analysts' recommendations: Invivyd, Inc.

Press Releases: Invivyd, Inc.

News in other languages: Invivyd, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Invivyd, Inc.

ETFs: Invivyd, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-25	Invivyd to Participate at the 8th Annual Evercore Healthcare Conference	GL
11-25	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329, Targeting 2H 2026 IND Readiness	AQ
11-24	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness	GL
11-18	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants	GL
11-17	Invivyd Announces Proposed Public Offering of Common Stock	GL

31/03/22	Adagio Therapeutics annonce que l'ADG20 (adintrevimab) est le premier anticorps monoclonal à répondre aux critères d'évaluation primaires ayant une importance statistique dans l'ensemble de la prophylaxie pré et post-exposition et du traitement pour la COVID-19, et prévoit de demander une autorisation d'utilisation d'urgence aux États-Unis
31/03/22	Adagio Therapeutics anuncia que ADG20 (adintrevimab) es el primer anticuerpo monoclonal que cumple con los principales criterios de valoración con importancia estadística en la profilaxis pre-exposición (PrEP) y profilaxis post-exposición (PEP).y tratamiento de COVID-19 y planea solicitar autorización de uso de emergencia en Estados Unidos
31/03/22	Adagio Therapeutics gibt bekannt, dass ADG20 (Adintrevimab) der erste monoklonale Antikörper ist, der die primären Endpunkte der Prophylaxe vor und nach Exposition sowie der Behandlung von COVID-19 mit statistischer Signifikanz erreicht hat, und plant die Beantragung der Notfallzulassung in den USA
14/01/22	Adagio Therapeutics resume actividad neutralizante de ADG20 contra variantes de SARS-CoV-2 y describe iniciativas para abordar la variante ómicron
14/01/22	Adagio Therapeutics legt zusammenfassende Ergebnisse zur neutralisierenden Wirkung von ADG20 gegenüber SARS-CoV-2-Varianten vor und stellt Initiativen zur Bekämpfung von Omikron vor

1 day	+0.45%
1 week	-4.29%
Current month	-8.23%
1 month	+59.29%
3 months	+123.56%
6 months	+130.11%
Current year	+403.27%

1 week	2.09	2.6
1 month	1.38	3.07
Current year	0.35	3.07
1 year	0.35	3.07
3 years	0.35	5.2
5 years	0.35	78.82
10 years	0.35	78.82

Manager	Title	Age	Since
William Duke CEO	Chief Executive Officer	52	29/05/2024
Robert Allen CTO	Chief Tech/Sci/R&D Officer	56	11/04/2023
Timothy Lee PRN	Corporate Officer/Principal	-	31/05/2024

Director	Title	Age	Since
Terry McGuire BRD	Director/Board Member	69	30/09/2020
Ajay Royan BRD	Director/Board Member	45	25/03/2025
Tamsin Berry BRD	Director/Board Member	44	21/06/2022

Name	Weight	AuM	Varia. Jan 1.	Investor
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	0%	7 M€	+13.97%	-
VANGUARD US TOTAL MARKET SHARES INDEX ETF	0%	293,477 M€	+8.97%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INVIVYD, INC.	+0.45%	-4.29%	+250.52%	-3.88%	518M
ELI LILLY AND COMPANY	-0.41%	-8.51%	+21.75%	+169.59%	908B
JOHNSON & JOHNSON	-0.27%	-2.71%	+34.20%	+12.89%	488B
ABBVIE INC.	-1.15%	-0.69%	+28.12%	+38.14%	404B
ROCHE HOLDING AG	+0.26%	+0.52%	+22.55%	+0.86%	331B
ASTRAZENECA PLC	+0.58%	-3.00%	+29.69%	+21.60%	280B
NOVARTIS AG	+0.19%	+2.33%	+18.85%	+27.26%	256B
MERCK & CO., INC.	-1.16%	-4.69%	-1.63%	-9.38%	250B
NOVO NORDISK A/S	+1.24%	-0.42%	-60.31%	-30.97%	212B
AMGEN INC.	-3.02%	-4.26%	+18.55%	+15.54%	183B
Average	-0.08%	-2.25%	+36.23%	+24.17%	331.35B
Weighted average by Cap.	+0.06%	-3.09%	+17.73%	+55.22%

	2025 *	2026 *
Net sales	50.74M 43.62M 40.86M 38.08M 70.34M 4.57B 76.51M 478M 185M 2.16B 190M 186M 7.89B	138M 118M 111M 103M 191M 12.39B 208M 1.3B 501M 5.85B 517M 506M 21.4B
Net income	-60.44M -51.96M -48.67M -45.37M -83.8M -5.44B -91.15M -569M -220M -2.57B -227M -222M -9.39B	-45.32M -38.96M -36.5M -34.02M -62.83M -4.08B -68.34M -427M -165M -1.93B -170M -166M -7.04B
Net Debt	-	-